TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03418506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMOKELESS TOBACCO AWARENESS PROGRAM
Description: A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
Study: NCT00161382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV, STD, and pregnancy prevention curriculum
Description: This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard sexual education curriculum
Description: Control curriculum consists of standard sexual education.
Study: NCT02227654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abnormal Ovarian Ultrasound
Description: Ultrasound
Study: NCT04542850

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 5-ALA-Phosphate + SFC (5-ALA + SFC)
Description: Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days
Study: NCT03522571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental gingivitis
Description: Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental gingivitis
Description: Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
Study: NCT02448121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cell graft
Description: All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
Study: NCT01782508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: a selectively inhibits the KIT protein tyrosine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon
Description: Interferon belongs to the large class of glycoproteins known as cytokines.
Study: NCT01784666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Study: NCT03763760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study: NCT01742780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Humerus Intraosseous Vascular Access
Description: EZ-IO Intraosseous Vascular Access System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Humerus Intraosseous Vascular Access
Description: EZ-IO Intraosseous Vascular Access System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Humerus Intraosseous Vascular Access
Description: EZ-IO Intraosseous Vascular Access System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Humerus Intraosseous Vascular Access
Description: EZ-IO Intraosseous Vascular Access System
Study: NCT04556344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional skills
Description: 3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Short free talk and relaxation
Description: 3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
Study: NCT01041261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BariatrX Essentials 360 Treatment
Description: Medical food
Study: NCT03257358

Intervention type: DRUG
Group type: OTHER
Intervention: Fingolimod
Description: Commercially available 0.5mg hard capsules, taken orally once per day

Intervention type: DRUG
Group type: OTHER
Intervention: Fingolimod
Description: Commercially available 0.5mg hard capsules, taken orally once per day
Study: NCT00203385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Depakote up to 2000mg/d
Study: NCT02418520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miswak
Description: Oral hygiene with Miswak chewing sticks and normal tooth brush
Study: NCT02923154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01114737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride
Description: A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
Study: NCT04133168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Cardiac Cryoablation System
Description: The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories
Study: NCT02987608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Up
Description: Smartphone phone app
Study: NCT00457392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib 37.5 mg daily by oral capsules in a continuous regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo daily by oral capsules in a continuous regimen
Study: NCT00686673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing tailored message on disclosing terminal illness
Description: an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
Study: NCT04995718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET)
Description: Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
Study: NCT01084031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: intravenous propofol with sevoflurane inhalation induction
Study: NCT01691690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Description: Acetaminophen IV (15 mg/kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush
Description: Saline placebo will be infused intraoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane for anesthesia induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane for anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide/Oxygen
Description: Combination of NO2 \& O2 for anesthesia induction.
Study: NCT00845104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies
Study: NCT00388960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study: NCT00686673

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Providing non-tailored message on pain control
Description: an attention control group that receives non-tailored video and manual on pain control
Study: NCT00388960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study: NCT02207478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENB
Description: ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GS-TBLB-X-ray
Description: A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GS-TBLB-X-ray
Description: A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
Study: NCT00845494

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive behavioral intervention
Description: The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
Study: NCT00388960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study: NCT02439203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04624828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy (ADT)
Description: ADT as for clinical practice:~* for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~* for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression
Study: NCT02946944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil/apixaban
Description: After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
Study: NCT02429817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium-99m - Diethylenetriaminepentaacetic acid
Description: 99mTc-DTPA solution placed on the nebulizer reservoir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium-99m - Diethylenetriaminepentaacetic acid
Description: 99mTc-DTPA solution placed on the nebulizer reservoir
Study: NCT03581071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-143
Study: NCT04624828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immune evaluation
Description: We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.
Study: NCT02429817

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aeroneb Solo
Study: NCT01691690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous Oxide/Oxygen
Description: Combination of NO2 \& O2 for anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine 0.1 mg/kg given prior to intubation.
Study: NCT02429817

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Study: NCT02946944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apixaban
Description: After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
Study: NCT03044678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH for Success
Description: Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Study
Description: Books for youth about anxiety management
Study: NCT03372096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization
Description: LC Bead LUMI is a spherical polyvinyl alcohol embolic particle that incorporates radiopaque moieties. Once a catheter has been fluoroscopically guided into the target vessel, the beads are then injected, causing obstruction at the arteriole level until the desired degree of embolization has occurred.
Study: NCT02050191

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: www.princetonlivingwell.com